04/11/2021 Small Caps – Invex Therapeutics chases global registration of Presendin to treat idiopathic intracranial hypertension
26/07/2021 Invex Therapeutics closes busy quarter of development on Presendin for idiopathic intracranial hypertension
15/06/2021 Invex Therapeutics receives US FDA feedback on planned Presendin trial targeting idiopathic intracranial hypertension
27/01/2021 Small Caps – Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder
